Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.7400 (-0.3%) ($11.7400 - $11.7400) on Tue. Dec. 20, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.91% (three month average) | RSI | 46 | Latest Price | $11.7400(-0.3%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(43%) IWC(42%) IWM(42%) IWN(41%) | Factors Impacting FOLD price | FOLD will decline at least -1.455% in a week (0% probabilities). VXX(-12%) VIXM(-12%) XLU(-10%) ARKG(-9%) TLT(-8%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.455% (StdDev 2.91%) | Hourly BBV | -0.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $12 | 5 Day Moving Average | $12.03(-2.41%) | 10 Day Moving Average | $12.06(-2.65%) | 20 Day Moving Average | $12(-2.17%) | To recent high | -7.7% | To recent low | 17.4% | Market Cap | $3.032b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |